3 Places The Allergan Tribal Deal May Face Pushback
Law360, New York (October 12, 2017, 7:14 PM EDT) -- Allergan PLC's controversial attempt to shield patents for dry-eye drug Restasis from review at the Patent Trial and Appeal Board by making a deal with a Native American tribe has drawn intense scrutiny, amid concerns from groups including lawmakers and generic-drug companies. Here are three places where the deal will be closely examined.
It's been a little more than four weeks since Allergan announced it would transfer six patents for Restasis to the St. Regis Mohawk tribe, and then license them back. It believes that the tribe, as a sovereign nation, is immune to patent challenges in inter partes review...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!